ONC vs. PCVX: BeOne Medicines vs. Vaxcyte Stock Comparison
How do BeOne Medicines (ONC) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BeOne Medicines (ONC) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Vaxcyte (PCVX) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ONC | PCVX |
|---|---|---|
| Name | BeOne Medicines Ltd. American Depositary Shares | Vaxcyte Inc. |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 46.49 billion USD | 10.11 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | February 3, 2016 | June 12, 2020 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ONC | PCVX |
|---|---|---|
| Total Return (1Y) | 30.59% | 59.00% |
| Total Return (3Y, Annualized) | 30.15% | 11.29% |
| Total Return (5Y, Annualized) | 2.48% | 21.60% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ONC | PCVX |
|---|---|---|
| Volatility (1Y, Annualized) | 35.90% | 56.01% |
| Beta (5Y) | 0.59 | 1.26 |
| Max Drawdown (5Y) | -68.89% | -76.22% |
| Avg. Volume (3M) | 405.29K | 2.12M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ONC | PCVX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.73 | 0.98 |
| Sortino Ratio (1Y) | 1.15 | 1.76 |
Profitability
ROE (TTM)
Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile BeOne Medicines (ONC) reports 18.40%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-42.68%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- PCVX
- -42.68%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BeOne Medicines (ONC) at 13.86% retains a top-quartile share of revenue as profit, ahead of Vaxcyte (PCVX) at 0.00%, which keeps about the industry-typical share.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- PCVX
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ONC | PCVX |
|---|---|---|
| ROE (TTM) | 18.40% | -42.68% |
| ROA (TTM) | 8.42% | -24.98% |
| Net Margin (TTM) | 13.86% | 0.00% |
| Operating Margin (TTM) | 22.15% | 0.00% |
| Gross Margin (TTM) | 89.39% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: BeOne Medicines (ONC) reports revenue growth of 40.23%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.
EPS Growth
Neither BeOne Medicines (ONC) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ONC | PCVX |
|---|---|---|
| Revenue Growth (YoY) | 40.23% | -- |
| Revenue Growth (3Y CAGR) | 55.69% | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both BeOne Medicines (ONC) at 3.55 and Vaxcyte (PCVX) at 4.56 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.56
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- PCVX
- 4.56
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both BeOne Medicines (ONC) at 0.35 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- PCVX
- 0.09
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ONC | PCVX |
|---|---|---|
| Current Ratio (MRQ) | 3.55 | 4.56 |
| Debt / Equity (MRQ) | 0.35 | 0.09 |
| Net Debt / EBITDA | -2.80 | -- |
Dividends
Dividend Yield (TTM)
Neither BeOne Medicines (ONC) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BeOne Medicines (ONC) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- PCVX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ONC | PCVX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: BeOne Medicines (ONC) trades at 52.17 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- PCVX
- --
P/S Ratio (TTM)
A sales-based read is only available for BeOne Medicines (ONC), whose P/S ratio of 7.04 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- PCVX
- --
P/B Ratio (MRQ)
Vaxcyte (PCVX) at 3.83 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
PCVX
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.83
- Max
- 13.53
- Q3
- 6.54
- PCVX
- 3.83
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ONC | PCVX |
|---|---|---|
| P/E Ratio (TTM) | 52.17 | -- |
| P/S Ratio (TTM) | 7.04 | -- |
| P/B Ratio (MRQ) | 7.98 | 3.83 |
| Free Cash Flow Yield (TTM) | 2.21% | -5.24% |